QueenslandXRay

PSMA PET
NEW MEDICARE ITEM

From **1 July 2022,** two new items will be introduced for prostate-specific membrane antigen (PSMA) PET study, for patients with prostate cancer.

ITEM 61563 – INITIAL STAGING

The specialist or consultant physician **is to record** in the clinical notes and the request that the patient:

- **Has intermediate to high-risk prostate adenocarcinoma** ***(as defined below)***
- **Has previously been untreated; AND**
- **Is considered suitable for locoregional therapy with curative intent.**

Benefits are payable once in a patient's lifetime.

- Patients with **intermediate risk** prostate adenocarcinoma can be defined as having at least one of the following risk factors in the absence of any high-risk features: PSA of 10-20 ng/ml, or Gleason score of 7 or International Society of Urological Pathology (ISUP) grade group 2 or 3, or Stage T2b.
- Patients with **high-risk** prostate adenocarcinoma can be defined as having at least one of the following risk factors: PSA >20 ng/ml, or Gleason score >7 or ISUP grade group 4 or 5, or Stage T2c or ≥ T3.

ITEM 61564 - RESTAGING

The specialist or consultant physician **is to record** in the clinical notes and the request that the patient:

- **Has intermediate to high-risk prostate adenocarcinoma; AND**
- **Has undergone prior locoregional therapy and is considered suitable for further locoregional therapy.**

Benefits are payable for a maximum of two services in a patient's lifetime.

This item can be claimed by patients with:

- A PSA increase of 2ng/ml above the nadir after radiation therapy; OR
- Failure of PSA levels to fall to undetectable levels; OR
- Rising PSA serum after a radical prostatectomy.

Please scan here
to view our
Billing Guide

For more information on billing and PET/CT locations,
visit our online Billing Guide **qldxray.com.au/billingguide**

May 2022